Home » Posts tagged with » Bristol-Myers Squibb
EC approves Reblozyl for transfusion-dependent anemia in adults

EC approves Reblozyl for transfusion-dependent anemia in adults

Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the treatment of transfusion-dependent anemia in adult patients. The approval of Reblozyl is for transfusion-dependent anemia caused by very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had […]

Bristol-Myers Squibb wraps up $74bn acquisition of Celgene

Bristol-Myers Squibb has wrapped up its $74 billion acquisition of Celgene having got regulatory approval from all government authorities necessary for closing the merger agreement along with approvals from stockholders of the two companies. Celgene has now become a fully-owned subsidiary of Bristol-Myers Squibb and as per the merger terms, shareholders of the former have […]

Continue reading …
FTC clears decks for Bristol-Myers Squibb acquisition of Celgene

Bristol-Myers Squibb acquisition of Celgene : US pharma giant Bristol-Myers Squibb said that the US Federal Trade Commission (FTC) has given its clearance for its previously announced $74 billion acquisition of American biotech company Celgene. The FTC has accepted the proposed consent order regarding the pending merger of Bristol-Myers Squibb and Celgene, thereby allowing the […]

Continue reading …
Amgen to acquire Celgene psoriasis drug Otezla for $13.4bn

Amgen acquisition of Otezla : Amgen has agreed to acquire global rights to Celgene’s psoriasis drug Otezla (apremilast) for $13.4 billion, which includes $2.2 billion in expected future cash tax benefits. The deal is being executed to pave way for regulatory approval for the previously announced Bristol-Myers Squibb acquisition of Celgene in a deal worth […]

Continue reading …
US biotech company Celgene to be acquired by Bristol-Myers Squibb for $74bn

Bristol-Myers Squibb acquisition of Celgene : US biotech company Celgene has agreed to be acquired by Bristol-Myers Squibb in a stock and cash deal worth about $74 billion, as per the latest pharma acquisition news. The merger of the two US pharma companies will form a specialty biopharma company focused on developing high-value innovative medicines […]

Continue reading …
Vedanta Biosciences secures $27m to advance microbiome-derived drugs

US clinical stage company Vedanta Biosciences has raised $27 million in a Series C financing round to help it advance its pipeline of microbiome-derived product candidates. Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, Invesco Asset Management, Seventure Partners, and the company’s founder PureTech Health took part in the new investment round. Vedanta […]

Continue reading …
BMS’ Opdivo flops in CheckMate -331 trial in small cell lung cancer

Bristol-Myers Squibb (BMS) cancer drug Opdivo (nivolumab) failed to meet the primary endpoint of the phase 3 CheckMate -331 trial in small cell lung cancer patients whose condition relapsed after platinum-based chemotherapy treatment. Opdivo could not significantly improve overall survival in the patients in comparison to current standard of care chemotherapy of topotecan or amrubicin […]

Continue reading …
BMS, Compugen to trial COM701 Opdivo combo in advanced solid tumors

US biopharma company Bristol-Myers Squibb (BMS) has entered into a clinical collaboration with Compugen to evaluate the combination of its cancer drug Opdivo (nivolumab) with the Israeli genomics-based drug and diagnostic discovery company’s COM701 in advanced solid tumors. COM701 is being investigated by Compugen as an anti-PVRIG antibody while the cancer drug Opdivo is a […]

Continue reading …